Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

F. Meric-Bernstam, H. Arkenau, B. Tran, R. Bahleda, R. Kelley, C. Hierro, D. Ahn, A. Zhu, M. Javle, R. Winkler, H. He, J. Huang, L. Goyal

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)v100
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Jun 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this